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ConCeptual errors in the interpretation of 
miCroglial aCtivation
The initial understanding of what constitutes an activated micro-
glial cell was simple and straightforward – activated microglia 
were identified as reactive mononuclear elements responding to 
acute CNS injury in vivo (Oehmichen and Huber, 1976). These 
experiments represented a modern day extension of classic experi-
ments performed by Metchnikoff in the late 1800s in that they 
were focused on studying the inflammatory response, only this 
time in the brain. There was little doubt that activated microglia 
were part of an acute cellular response to an injurious stimulus, 
which for Oehmichen and Huber consisted of implanting glass 
cover slips into the rabbit brain. A more sophisticated paradigm 
of eliciting microglial activation whose origins date back to the 
work of Nissl at the turn of the 20th century, and advocated by 
Kreutzberg and colleagues beginning in the 1960s was the facial 
nerve axotomy paradigm. In this model, an acute and local neu-
roinflammatory response (microglial activation) can be induced in 
the facial nucleus simply by cutting the peripheral axons of cranial 
nerve VII. Although Kreutzberg and colleagues did not use the 
term “inflammation” but usually spoke of microglial activation, 
it was implicit because microglial activation represents a cellular 
reaction to injury, which in essence constitutes the definition of 
inflammation according to textbooks of pathology. Importantly, 
axotomy-induced microglial activation is associated both tempo-
rally and spatially with the successful regeneration of axotomized 
motoneurons,  providing  an  unambiguous  association  between 
microglial activation and the natural wound healing response, and 
clearly supporting a beneficial role for activated microglia.
The concept of microglial activation changed in the 1980s when 
researchers began to model it in vitro. Pioneering work done by 
Giulian and Baker (1986) established a relatively simple proce-
dure for isolating and maintaining microglial cells in the culture 
dish, and their method quickly became the procedure of choice 
introduCtion
One might reasonably argue that a microglial renaissance occurred 
during the mid-to late 1980s. Although anatomists of the early 
20th century, such as Nissl and del Rio Hortega, had already made 
seminal contributions toward understanding microglial biology, 
for reasons unknown microglia remained largely hidden away 
from mainstream neuroscience for much of the decades follow-
ing these early studies. During the 1970s and well into the 1980s 
the one key issue dominating microglial neurobiology concerned 
their embryological origin, i.e., whether the cells are of mesoder-
mal or neuroectodermal origin (Theele and Streit, 1993). Many 
would now consider this question resolved in favor of a mesodermal 
lineage, but rapid developments in the field of neural precursor 
cells may once again bring the ontogeny issue to the forefront for 
reconsideration.
The rebirth of microglia in the 1980s occurred because of 
two major developments: methods for culturing microglial cells 
in vitro and reagents for visualizing cells in situ became available. 
These advances were critical for stimulating renewed interest in 
the almost forgotten “third element” of Cajal as is abundantly 
evident now, some 20 years later, by the explosion of published 
papers on microglial cells. However, excitement over the rediscov-
ery of microglia also produced a major misconception regarding 
functional roles of activated microglia, namely, that microglial 
activation is harmful to neurons in the CNS. Thus, with regard to 
the question posed in this special issue: where did we get lost, the 
short answer is, we got lost early on by misinterpreting biological 
functions of microglia. The purpose of this paper is to describe 
how this misconception came about and how it became entan-
gled with the concept of detrimental neuroinflammation which 
is now believed by many to underlie not only Alzheimer’s disease 
(AD) pathogenesis but a number of other major neurodegenera-
tive conditions, including Parkinson’s disease, amyotrophic lateral 
sclerosis and HIV-associated dementia.
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for many other laboratories interested in studying the biological 
functions of microglia. In their initial as well as in subsequent 
papers, Giulian and colleagues emphasized the production of a 
prototypical proinflammatory cytokine, interleukin-1 (IL-1), by 
ameboid microglia (so-called because of their resemblance to mac-
rophages), which was reaffirmed by Hetier et al. (1988) just a cou-
ple of years later by showing that IL-1 mRNA synthesis was induced 
in these cultured cells following their stimulation with bacterial 
lipopolysaccharide (LPS). With this introduction to neurobiology 
of LPS-mediated macrophage activation, already well-established 
and accepted in immunology circles, the flood gates were opened 
for studying microglial activation in vitro. Countless studies have 
since then been performed using various modifications of the LPS 
model as well as other immunostimulatory paradigms for studying 
activated microglia in vitro. However, most of these studies have 
not taken into consideration the fact that microglia activated by 
LPS in vitro behave very differently than microglia activated by 
injured neurons in the brain. We have previously discussed this 
discrepancy between in vivo and in vitro concepts of microglial 
activation (Streit et al., 1999), pointing out that the generation of 
microglial cell cultures involves extreme brain damage (chopping 
and trituration of dissected tissues) inevitably causing immedi-
ate activation of microglia and their transformation into brain 
macrophages.  When  these  activated  microglia-derived  brain 
macrophages are additionally stimulated with LPS, the result is 
superactivated cells that produce not only copious quantities of 
IL-1 but many other secretory products. It seems that cells treated 
in this manner are activated to a maximal extent and are near the 
breaking point; indeed more recent work shows that LPS-mediated 
overactivation leads to microglial cell death (Liu et al., 2001). Thus, 
one key juncture where we got lost was in the silent assumption 
that cultured microglia unstimulated by LPS were representative 
of resting microglia in the normal brain, and that LPS-activated 
cells were analogous to activated microglia in the damaged brain. 
Any extrapolations made from such in vitro data are therefore 
unlikely to apply to most in vivo scenarios of microglial activation 
with the possible exception of a bacterial CNS infection. Case in 
point, ameboid microglia in vivo do not produce IL-1 (Hurley 
et al., 1999), as suggested by in vitro studies (Giulian et al., 1986). 
Moreover, the in vitro findings on microglial IL-1 production 
likely caused many to assume that whenever activated microglia 
were present in situ the cells produced IL-1 in a sustained manner. 
However, IL-1 production in vivo varies substantially and even 
in cases of severe CNS damage, such as spinal cord trauma, the 
duration of IL-1 production is limited to the first 24 h post-injury 
after which it drops to control levels (Streit et al., 1998). During 
the acute neuroinflammatory reaction in response to facial nerve 
axotomy IL-1 mRNA levels are very low and essentially the same 
as in uninjured control tissues (Streit et al., 1998). In addition to 
IL-1, which is often thought of as a potentially harmful cytokine 
associated with chronic inflammatory states, such as rheumatoid 
arthritis, other potentially damaging substances were found to 
be produced by activated microglia in vitro. Perhaps most nota-
ble and influential in this regard was the early study by Colton 
and Gilbert (1987) showing that microglia activated by zymosan 
can produce superoxide anions. Although the authors at the time 
presented their findings in the context of a bactericidal action of 
activated microglia, the data were extrapolated later on by many 
others to support the idea that activated microglia contribute to 
oxidative stress in the injured and diseased brain. While in vitro 
studies continued to gain momentum and eventually produced a 
picture of microglia as neurotoxic effector cells (Boje and Arora, 
1992; Chao et al., 1992; Giulian et al., 1993), other researchers 
were studying microglial activation in a variety of in vivo brain 
injury paradigms, as well as in the diseased human brain, taking 
advantage of the availability of new antibodies that allowed the 
visualization of microglia in situ.
Soon after the introduction of in vitro methods, McGeer et al. 
(1987) reported in a landmark paper the presence of reactive 
(activated) microglia in the brains of humans with AD. Their 
study together with another one by Rogers et al. (1988) 1 year 
later, and the in vitro data showing production of potentially 
harmful substances by activated microglia would set the stage for 
development of the notion that detrimental neuroinflammation 
plays a major role in AD pathogenesis. McGeer’s discovery was 
made possible by the availability of antibodies directed against 
major histocompatibility complex (MHC) antigens, which are 
well-known recognition molecules essential for mediating specific 
cell–cell interaction in the immune system, most significantly 
antigen presentation. Their findings were spectacular because of 
a prevailing view at the time that the brain is immunologically 
quiescent, i.e., an immunologically privileged organ where lym-
phatic drainage and MHC antigen expression are absent. However, 
McGeer’s identification of activated microglia by virtue of the 
fact that these cells were expressing MHC class II molecules was 
not entirely correct because MHC II expression occurs promi-
nently also on non-activated microglia and perivascular cells in 
the normal human and animal brain (Craggs and Webster, 1985; 
Hayes et al., 1987; Streit et al., 1989). Nonetheless, the notion 
that MHC II expression can serve as an objective biomolecu-
lar marker for activated microglia was seemingly corroborated 
by subsequent animal studies that showed increases in MHC II 
expression on a subset of microglial cells following experimen-
tal lesions (Akiyama et al., 1988; Streit et al., 1989; Smetanka 
et al., 1990), encouraging its widespread acceptance. The idea 
that neuroinflammatory processes are involved in AD was but-
tressed further by additional findings from the McGeer group 
showing presence of complement proteins and integrins in the 
AD brain (McGeer et al., 1989; Akiyama and McGeer, 1990), as 
well as by findings showing presence of IL-1 immunoreactive 
microglia in Down’s and AD cases (Griffin et al., 1989). Pretty 
soon, a large number of other inflammatory mediators, including 
many cytokines, were being added to the list of substances thought 
to be consistently increased in the AD brain and by the time a 
major review on AD and neuroinflammation was published in 
2000 (Akiyama et al., 2000), the notion was firmly embedded in 
mainstream thinking. A potential problem with all of these studies 
focused on measuring various inflammatory molecules in the AD 
brain is that most if not all of the inflammatory proteins (similar 
to MHC antigens) are also expressed in non-AD brains, and that 
levels of these are likely to vary substantially in both populations 
depending on whether or not peripheral infections are present. 
Thus, any future work along these lines should exclude subjects 
with infectious comorbidities.Frontiers in Aging Neuroscience  www.frontiersin.org  June 2010  | Volume 2  | Article 22  |  3
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aggregations at amyloid plaques. Aβ peptides had also been shown 
to be neurotoxic in vitro (Yankner et al., 1989), which probably 
served to encourage this line of reasoning, although in the same 
year and in the same journal a report appeared describing a neu-
rotrophic effects of Aβ peptides in vitro (Whitson et al., 1989). 
Conflicting findings like these underscore the potential fallacies 
associated with in vitro experimentation, where outcomes can be 
influenced profoundly by small variations in any one of a number 
of experimental parameters. In any event, a key question within 
the current context is, does the presence of amyloid deposits in 
AD brain represent a persistent injurious stimulus that incites 
chronic neuroinflammation? The answer is, probably not, because 
despite numerous histopathological studies claiming presence of 
microglial activation around amyloid deposits, a closer look at 
these allegedly activated cells has revealed that microglia associ-
ated with senile (neuritic) plaques more times than not display 
a dystrophic rather than an activated morphology (Streit et al., 
2009). Moreover, the fact that microglia become clustered at senile 
plaques is by itself not indicative of an inflammatory reaction 
but instead is more likely to reflect an abnormal cellular reaction 
triggered by presence of amyloid fibrils. It is known that diffuse, 
non-fibrillar (early) amyloid deposits, even when extensive, do not 
elicit microglial changes (Ohgami et al., 1991; Mackenzie et al., 
1995; Streit et al., 2009), and thus any microglial changes that 
have been associated with more advanced amyloid plaques are 
likely to be the result of altered chemistry of amyloid peptides. 
In addition, there is in vivo evidence showing increased presence 
of Aβ and amyloid precursor protein after traumatic head injury 
(Smith et al., 2003) strongly supporting the view that increased 
Aβ production in AD is the result rather than the cause of CNS 
disturbances. At the same time, it would be a stretch to postulate 
that extracellular deposition of amyloid peptides in and of itself 
constitutes an injury.
So, how does one reconcile the many histopathological descrip-
tions of activated microglia in AD with the claim made here that AD 
is not an inflammatory disease? First, if indeed microglial activation 
does occur at some point during the evolution of senile plaques, it 
does not necessarily have to be detrimental and cause AD neurofi-
brillary degeneration. Neurofibrillary tangles and neuropil threads 
are not limited to the vicinity of amyloid deposits and they occur 
during normal aging, as well as in other neurological diseases and 
in the absence of amyloid. Second, there is a good chance that non-
activated (especially dystrophic) microglia were misidentified as 
activated cells based not only on the false assumption that MHC II 
expression is an immunological marker for activated cells, but also 
because of only a superficial assessment of their morphology. In the 
late 1980s and early 1990s the idea of morphologically abnormal 
(dystrophic) microglia did not exist and with the excitement over 
the rediscovery of microglia researchers were quick to identify any 
non-ramified microglial cell as activated. Lastly, the possibility that 
microglial activation observable within the AD brain might be the 
result of infectious disease in the periphery has never been studied 
systematically; in other words, studies that have assessed neuroin-
flammation in AD did not make a distinction between AD cases 
with and without infectious disease comorbidities, which are quite 
common in AD patients. We know now that peripheral infections 
in humans are accompanied by prominent microglial activation 
aCute versus ChroniC inflammation and the role of 
amyloid-β protein
Another place where we got lost was by not differentiating between 
acute and chronic inflammation and distinguishing between a 
wound healing response and autoimmune disease, although I will 
maintain that neither contributes to AD neurodegeneration. While 
acute inflammation comprises the immediate and early reaction 
to an injurious event and is basically an adaptive response that 
paves the way for repair of the damaged site, chronic inflamma-
tion results from injurious stimuli that are persistent. There is no 
evidence of any injurious event in AD that would precipitate an 
inflammatory reaction, although some might argue that amyloid-β 
protein (Aβ) qualifies in this regard (see below). In the periphery, 
both acute and chronic inflammation are characterized by leuko-
cytic exudates consisting primarily of polymorphonuclear cells 
(neutrophils) in the former, and mononuclear cells (macrophages, 
lymphocytes, plasma cells) in the latter. In the CNS, because of 
the presence of the blood brain barrier, leukocytic exudates may 
or may not be part of acute neuroinflammation, the facial nerve 
axotomy paradigm being a premier example of this (Raivich et al., 
1998). The classic example of chronic neuroinflammation occur-
ring in the CNS is found in multiple sclerosis, a disease marked 
by prominent leukocytic infiltrates. While the underlying cause(s) 
of MS have not been identified, it is probably safe to say that the 
persistent injurious stimulus that accounts for MS neuroinflam-
mation is a myelin-related protein that has escaped self-tolerance 
and become an autoantigen, which is consistent with how experi-
mental autoimmune encephalomyelitis is induced in animals. With 
the chronic persistence of a CNS autoantigen there is a persistent 
accumulation of blood-derived mononuclear leukocytes in the 
CNS parenchyma, which mirrors the presence of leukocytic exu-
dates in peripheral inflammatory diseases, such as rheumatoid 
arthritis or polymyositis. It is the persistent presence of extensive 
leukocytic infiltrates that eventually produces tissue damage. In 
AD there are no lymphocytic infiltrates to speak of, making it 
very difficult to maintain that AD is an inflammatory disease. 
Nonetheless, it was assumed that the ostensible inflammation in 
AD is of a chronic and therefore detrimental nature because AD 
is after all an aging-related condition and a number of studies had 
shown a progressive increase in the expression of MHC class II 
antigens in the normal aging brain (Rogers et al., 1988; Perry et al., 
1993; Ogura et al., 1994; Sheffield and Berman, 1998), suggesting 
that normal aging is accompanied by inflammation. Also, the word 
“disease” implicitly carries the notion of chronicity and so it was 
assumed that whatever inflammatory changes were detected in 
AD had been there for some time when, in fact, it is impossible 
to say so from a one-time post-mortem histopathological obser-
vation. The idea that microglia are cytotoxic inflammatory cells 
that contribute towards neurodegeneration in AD was propagated 
and ostensibly corroborated through additional in vitro studies 
showing that when cultured microglial cells are stimulated with 
Aβ peptides they produce molecules which are toxic to cultured 
neurons (Meda et al., 1995; Giulian et al., 1996; Combs et al., 1999). 
The conclusion that Aβ deposits are inflammatogenic in the AD 
brain and incite detrimental inflammatory activity was at this 
point all but inevitable, especially since it seemed to be consistent 
with numerous prior histopathological descriptions of microglial Frontiers in Aging Neuroscience  www.frontiersin.org  June 2010  | Volume 2  | Article 22  |  4
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ConClusions
To sum up briefly where we got lost, most significant was the 
overinterpretation of cell culture data and the indiscriminate 
extrapolation of microglial cytotoxin production from an artifi-
cial in vitro environment to the human brain. There was a clear 
failure to recognize the disparity between microglial activation, 
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